Silence Therapeutics plc SLN
Silence Therapeutics plc (Nasdaq: SLN) is a hematology drug developer. Its lead program, Divesiran (SLN124), is in Phase 2 for Polycythemia vera. Its next catalyst on record is SLN365: Potential IND filing (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SLN365 — Potential IND filing (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Divesiran (SLN124) | Polycythemia vera | RNA (siRNA/ASO/mRNA) | Phase 2 |
| Zerlasiran (SLN360) | High lipoprotein(a) cardiovascular disease | RNA (siRNA/ASO/mRNA) | Phase 2 |
| SLN312 (AZD1705) | Dyslipidemia (ANGPTL3) | RNA (siRNA/ASO/mRNA) | Phase 1 |
| SLN548 | Complement-mediated renal disease (CFB) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| SLN365 | Hypercholesterolemia (GPR146) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| SLN098 | Obesity (INHBE) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Oct 18, 2026n/a Merck KGaA, Darmstadt, Germany entered into a definitive agreement to acquire Silence Therapeutics for $20.00 per ADS in an all-cash transaction valued at approximately $1.3 billion.
Merck KGaA, Darmstadt, Germany will acquire all outstanding ordinary shares of Silence. Upon completion of the transaction, Silence shareholders will receive $20.00 in cash per American Depositary Share.
Filing - Aug 10, 2026met Phase 2 SANRECO met primary endpoint: 88% responders on divesiran vs 19% on placebo (p<0.0001; 93.8% Q6W, 81.3% Q12W); phlebotomies 0.2 vs 2.1 per patient; well tolerated.
The primary endpoint was met, with a significantly higher proportion of clinical responders among divesiran-treated patients with PV compared to those who received placebo (88% for divesiran versus 19% for placebo; p<0.0001).
Filing - Jun 11, 2026positive Phase 1 follow-up at EHA 2026: 80 phlebotomies in 6 months pre-treatment vs 5 on treatment and 4 in 16-week follow-up (n=21); median 287 days to first phlebotomy among 14 patients; symptom improvement, no treatment-related SAEs.
In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.